fda compounding semaglutide GLP-1 compounding is now restricted to specific medical needs - Semaglutide FDAapproval Compounding of semaglutide will continue until at least May 22, 2025 Understanding FDA Compounding of Semaglutide: Navigating Regulations and Availability

Is compoundedsemaglutidegoing away The landscape surrounding semaglutide and its availability through compounding pharmacies has undergone significant shifts due to FDA oversight. This article aims to provide a comprehensive overview of the FDA compounding semaglutide regulations, clarifying the current status, legal implications, and what patients and healthcare providers need to knowHow to Qualify for Semaglutide: Requirements to Meet - Hers.

The FDA's Stance on Compounded Semaglutide

Historically, the FDA has addressed the shortage of semaglutide injection products, a crucial GLP-1 medication. In February 2025, the FDA declared the semaglutide shortage is over, which has had a direct impact on compounding practices. This resolution means that semaglutide is generally no longer eligible for general compounding.

It is crucial to understand that compounded "semaglutide" is not approved by the FDA. While compounded medications are not FDA approved, they can be lawfully marketed under specific conditions, such as complying with sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. However, the FDA has raised concerns about the compounding of semaglutide salts that may not have been adequately tested for safety or efficacy.Compound versions of some weight loss drugs to be restricted The agency is aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.2025年3月21日—The FDA issued guidance clarifying that 503A and 503B drug compoundersmust soon cease compounding semaglutide injection products.S. with potentially false product labeling.2025年10月29日—Note:Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved ...

Changes in Compounding Regulations

Following the FDA's announcement regarding the resolution of the semaglutide shortage, the agency issued guidance. This guidance clarified that 503A and 503B drug compounders must soon cease compounding semaglutide injection products. This led to deadlines for stopping the compounding of semaglutide and tirzepatide. For instance, compounding of semaglutide will continue until at least May 22, 2025, for 503B Pharmacies (also known as 503B Outsourcing Facilities). Subsequently, compounded semaglutide/tirzepatide will phase out by late May 2025, necessitating a transition to FDA-approved productsFDA ends GLP-1 compounding for semaglutide, tirzepatide.

The FDA's actions mean that many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. The FDA has halted the sale of off-brand Ozempic and other GLP-1 Drugs. This implies that compounded versions of these drugs made by smaller pharmacies and sold without FDA approval can no longer be legally produced or sold, with limited exceptions for specific medical needs.FDA clarifies policies for compounders as national GLP-1 ...

Current Status and Future Outlook

While the FDA declares semaglutide shortage over, spelling end to general compounding, compounded semaglutide is only available in certain situations.2024年8月27日—The federal Food Drug & Cosmetic Act (FD&C Act),prohibits compounding regularly, or in inordinate amounts, “any drug products that are ... GLP-1 compounding is now restricted to specific medical needs. Only licensed 503A / 503B pharmacies may prepare these drugs under very specific circumstances.

The FDA has also addressed concerns regarding unapproved GLP-1 Drugs Used for Weight Loss. The marketing trend of compounding GLP-1 receptor agonists with additives raises significant compliance concerns under FDA regulations. Furthermore, the Federal Food, Drug, and Cosmetic Act (FD&C Act) prohibits compounding regularly, or in inordinate amounts, certain drug products, including those that are not on the FDA's list of bulk drug substances for which there is a clinical need.FDA Announces End to Semaglutide Shortage, Impacting ...

For patients, understanding the distinction between FDA-approved semaglutide (like Ozempic and Wegovy) and compounded semaglutide is paramount. Compounded drugs are not approved by the U2025年2月25日—The Food and Drug Administration has determined the shortage ofsemaglutide injection products is resolved, and that it does not intend to take action..S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved medications. Patients should consult with their healthcare providers to determine the most appropriate and safe treatment options.FDA Announces End to Semaglutide Shortage, Impacting ...

Recent evaluations by the FDA have also indicated no evidence of an increased risk of suicidal ideation or behavior associated with the use of GLP-1 medications, which is a positive development for patient safety and awareness.

In summary, the FDA's evolving policies around compounding semaglutide reflect a commitment to ensuring drug safety and efficacyFDA has determined the shortage ofsemaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved.. While the era of widespread compounded semaglutide may be drawing to a close, understanding these regulatory changes is essential for informed healthcare decisions.